Should Spyre’s New Dual-Pathway HS Strategy and SKYLIGHT Trial Design Reshape the Spyre Therapeutics (SYRE) Narrative?

• In August 2026, Spyre Therapeutics announced SPY772, a new preclinical combination program pairing its long-acting anti-TL1A antibody SPY072 with the novel long-acting anti-IL-17A/F antibody SPY007, and reported the start of SKYLIGHT, a randomized, placebo-controlled Phase 2 proof-of-concept trial in approximately 150 adults with moderate-to-severe Hidradenitis Suppurativa receiving background bimekizumab therapy, with topline data planned for late 2027 or early 2028.
• This dual-inhibition approach in Hidradenitis Suppurativa positions Spyre Therapeutics to test a layered immunology strategy that could differentiate its pipeline in a complex inflammatory disease with limited treatment options.
• With these developments now underway, we’ll examine how the SKYLIGHT Phase 2 trial design shapes Spyre Therapeutics’ broader investment narrative.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

What Is Spyre Therapeutics' Investment Narrative?

To own Spyre Therapeutics, you have to believe in its TL1A-centered immunology platform becoming a meaningful player in inflammatory disease, despite zero revenue and persistent losses. The SKYLIGHT Phase 2 launch in Hidradenitis Suppurativa, on top of positive SPY002 UC data, reinforces the near-term catalyst stack around multiple readouts from SKYLINE and SKYWAY in 2026–2028 rather than changing it outright. What SPY772 really does is broaden the story: it points to a more ambitious layering strategy that could matter if early TL1A signals translate across diseases. In the short term, though, the biggest swing factors still look like clinical data quality, cash burn, and future use of the sizable ATM capacity, all against a share price that has already moved very sharply over the past year.

However, one key financing risk here is easy to overlook until it matters most. Upon reviewing our latest valuation report, Spyre Therapeutics' share price might be too optimistic.

Exploring Other Perspectives

Only one Simply Wall St Community fair value sits at US$124.71, so you are not seeing a wide spread of opinions yet. Against that, the recent SKYLIGHT launch and heavy cash usage highlight why many market participants will be watching future trial data and funding choices closely, and why it can help to compare multiple viewpoints before deciding how to treat the current share price.

Explore another fair value estimate on Spyre Therapeutics - why the stock might be worth as much as 17% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Spyre Therapeutics research is our analysis highlighting 4 important warning signs that could impact your investment decision.
• Our free Spyre Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Spyre Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com